D.A. Davidson & CO. Invests $141,000 in Atyr PHARMA INC (NASDAQ:ATYR)

D.A. Davidson & CO. purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 39,000 shares of the company’s stock, valued at approximately $141,000.

Other large investors have also recently bought and sold shares of the company. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA during the fourth quarter worth approximately $36,000. JPMorgan Chase & Co. grew its holdings in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after buying an additional 10,754 shares in the last quarter. Finally, Kingswood Wealth Advisors LLC bought a new position in Atyr PHARMA during the 4th quarter worth $170,000. 61.72% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on ATYR shares. Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald started coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating for the company. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Price Performance

ATYR stock opened at $3.87 on Friday. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a market cap of $324.86 million, a price-to-earnings ratio of -4.12 and a beta of 1.10. The company’s fifty day simple moving average is $3.70 and its 200 day simple moving average is $2.94. Atyr PHARMA INC has a 12-month low of $1.42 and a 12-month high of $4.66.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.